

**Author(s):** Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

**Question:** Should monoclonal antibody Lenzilumab compared to standard treatment be used for COVID-19 patients?

**Setting:** Inpatient

Certainty assessment							N° of patients		Effect		Certainty
N° of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Monoclonal antibody Lenzilumab	Standard treatment	Relative (95% CI)	Absolute (95% CI)	

**All-cause mortality**

1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	not serious	none	23/236 (9.7%)	34/243 (14.0%)	<b>RR 0.70</b> (0.42 to 1.15)	<b>42 fewer per 1.000</b> (from 81 fewer to 21 more)	⊕⊕⊕⊕ HIGH
----------------	-------------------	-------------	-------------	-------------	-------------	------	---------------	----------------	----------------------------------	---	--------------

**Number of patients with any adverse event**

1 <sup>1</sup>	randomised trials	not serious	not serious	not serious	not serious	none	68/255 (26.7%)	84/257 (32.7%)	<b>RR 0.82</b> (0.62 to 1.07)	<b>59 fewer per 1.000</b> (from 124 fewer to 23 more)	⊕⊕⊕⊕ HIGH
----------------	-------------------	-------------	-------------	-------------	-------------	------	----------------	----------------	----------------------------------	--	--------------

**References**

1. Temesgen Z, Burger CD, Baker J, Polk C, Libertin C, Kelley C, et al. Lenzilumab efficacy and safety in newly hospitalized covid-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial. medRxiv [Preprint]. 2021 May 5:2021.05.01.21256470. doi: 10.1101/2021.05.01.21256470.